# Challenbio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/challenbio

- Industry: Medical Devices & Equipment
- Headquarters: Beijing, China
- Website: www.challenbio.com/
- Total disclosed funding: $14M
- Latest round: Series B (Jul 28, 2026)
- Investors on record: 4

## About

Based in Beijing, China, and established in 2020, Beijing Challen Biotechnology Co., Ltd., trading under the name Challenbio, provides flow cytometry detection solutions for the biopharmaceutical and clinical diagnostic sectors. The founder of the company is Tiefu Liu who graduated from the College of Mechanical Engineering, Tsinghua University, and has participated in the R&D of clinical flow cytometer equipment at Mindray Beijing Research Institute in 2007. The company has R&D offices in Daxing and Changping and a wholly-owned subsidiary in Hunan. Its products have acquired CE certification. In July 2026, it raised tens of millions of CNY in series B++ funding led by Shangshi Fund. The company works with research institutions, hospitals, and biopharmaceutical enterprises to provide comprehensive flow cytometry systems. The hardware portfolio includes clinical devices such as the MateCyte, LongCyte, and ClinStellar spectrum systems, alongside scientific equipment like the FongCyte, ElaraCyte, and CytoStellar series. The firm also provides clinical immune assessment reagents integrated with volumetric absolute counting technology for automated clinical screening. The company generates revenue from B2B contracts for the commercial sale of flow cytometers and diagnostic reagent consumables to scientific research institutions and medical diagnostic centers. The company will use the series B++ funding to accelerate its clinical registration and industrialization of the next-generation fully automated flow cytometry analysis platform.

## Funding rounds

- Series B, Jul 28, 2026 — Shangshi Fund
- Series B, Mar 27, 2024, $14M — Lotus Lake Capital, Addor Capital
- Series A, Jul 21, 2022 — IDG Capital

## Investors

- IDG Capital (https://capitalatlas.ai/funds/idg-capital) — Series A
- Lotus Lake Capital (https://capitalatlas.ai/funds/lotus-lake-capital) — Series B
- Addor Capital (https://capitalatlas.ai/funds/addor-capital) — Series B
- Shangshi Fund (https://capitalatlas.ai/funds/shangshi-fund) — Series B